Cargando…

A prospective randomized comparison of the efficacy of standard antiviral therapy versus ultrasound-guided thoracic paravertebral block for acute herpes zoster

OBJECTIVES: To evaluate the effectiveness of repetitive thoracic paravertebral block (TPVB) under ultrasound (US) guidance for acute pain associated to herpes zoster (HZ) and its prophylactic effects on post-herpetic neuralgia (PHN). METHODS: Patients who suffered from acute pain associated to HZ wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yingchao, Li, Bingsi, Sun, Lei, He, Xin, Wu, Shuang, Shi, Fan, Niu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815626/
https://www.ncbi.nlm.nih.gov/pubmed/35107389
http://dx.doi.org/10.1080/07853890.2022.2031267
_version_ 1784645287615135744
author Ma, Yingchao
Li, Bingsi
Sun, Lei
He, Xin
Wu, Shuang
Shi, Fan
Niu, Li
author_facet Ma, Yingchao
Li, Bingsi
Sun, Lei
He, Xin
Wu, Shuang
Shi, Fan
Niu, Li
author_sort Ma, Yingchao
collection PubMed
description OBJECTIVES: To evaluate the effectiveness of repetitive thoracic paravertebral block (TPVB) under ultrasound (US) guidance for acute pain associated to herpes zoster (HZ) and its prophylactic effects on post-herpetic neuralgia (PHN). METHODS: Patients who suffered from acute pain associated to HZ within 1 week of rash onset were randomized in a ratio of 1:1 to receive a seven-day course antiviral therapy, antiviral therapy with additional US-guided repetitive TPVB using transverse short axial (TSA) approach every 48 h for a week after antiviral therapy. All patients were allowed to receive rescue analgesics. The primary endpoint was HZ burden of illness (HZ-BOI) measured by a severity-by-duration composite pain assessment conducted 1-month post inclusion. Adverse events were also recorded. RESULTS: A total of 96 patients completed the entire 6-month follow-up. The BOI-30(AUC) was 112.5 (95%CI: 105.2, 119.9) in control group, and 82.7 (95%CI: 75.4, 90.1) in TPVB group (F = 32.252, p<.001) at D30 after inclusion. Compared with control group, significant reductions of BOI-30–90(AUC), and BOI-90–180(AUC) were observed in TPVB group (F = 11.392, p=.001 at D90; F = 7.467, p=.007 at D180, respectively). At 3 and 6 months after inclusion, the incidence of PHN in TPVB group was significantly lower than control group. Quality of life (QoL) in TPVB group also showed greater improvements at all the time points in all domains of EQ-5D-3L (p<.05). No serious adverse events were observed. CONCLUSIONS: US-guided repetitive TPVB significantly reduced the HZ-BOI and the PHN incidence compared to antiviral therapy alone. It might be considered as an early intervention and preventive strategy to the development of PHN after acute HZ. KEY MESSAGE: This is a prospective randomized comparative study. We made a hypothesis that US-guided repetitive thoracic paravertebral block (TPVB) using a transverse short axial (TSA) approach to treat thoracic herpes zoster (HZ) in acute phase could reduce the burden of illness associated to acute pain. Moreover, this therapy might be a feasible preventive strategy to reduce the incidence of post-herpetic neuralgia.
format Online
Article
Text
id pubmed-8815626
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88156262022-02-05 A prospective randomized comparison of the efficacy of standard antiviral therapy versus ultrasound-guided thoracic paravertebral block for acute herpes zoster Ma, Yingchao Li, Bingsi Sun, Lei He, Xin Wu, Shuang Shi, Fan Niu, Li Ann Med Neurology OBJECTIVES: To evaluate the effectiveness of repetitive thoracic paravertebral block (TPVB) under ultrasound (US) guidance for acute pain associated to herpes zoster (HZ) and its prophylactic effects on post-herpetic neuralgia (PHN). METHODS: Patients who suffered from acute pain associated to HZ within 1 week of rash onset were randomized in a ratio of 1:1 to receive a seven-day course antiviral therapy, antiviral therapy with additional US-guided repetitive TPVB using transverse short axial (TSA) approach every 48 h for a week after antiviral therapy. All patients were allowed to receive rescue analgesics. The primary endpoint was HZ burden of illness (HZ-BOI) measured by a severity-by-duration composite pain assessment conducted 1-month post inclusion. Adverse events were also recorded. RESULTS: A total of 96 patients completed the entire 6-month follow-up. The BOI-30(AUC) was 112.5 (95%CI: 105.2, 119.9) in control group, and 82.7 (95%CI: 75.4, 90.1) in TPVB group (F = 32.252, p<.001) at D30 after inclusion. Compared with control group, significant reductions of BOI-30–90(AUC), and BOI-90–180(AUC) were observed in TPVB group (F = 11.392, p=.001 at D90; F = 7.467, p=.007 at D180, respectively). At 3 and 6 months after inclusion, the incidence of PHN in TPVB group was significantly lower than control group. Quality of life (QoL) in TPVB group also showed greater improvements at all the time points in all domains of EQ-5D-3L (p<.05). No serious adverse events were observed. CONCLUSIONS: US-guided repetitive TPVB significantly reduced the HZ-BOI and the PHN incidence compared to antiviral therapy alone. It might be considered as an early intervention and preventive strategy to the development of PHN after acute HZ. KEY MESSAGE: This is a prospective randomized comparative study. We made a hypothesis that US-guided repetitive thoracic paravertebral block (TPVB) using a transverse short axial (TSA) approach to treat thoracic herpes zoster (HZ) in acute phase could reduce the burden of illness associated to acute pain. Moreover, this therapy might be a feasible preventive strategy to reduce the incidence of post-herpetic neuralgia. Taylor & Francis 2022-02-02 /pmc/articles/PMC8815626/ /pubmed/35107389 http://dx.doi.org/10.1080/07853890.2022.2031267 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Neurology
Ma, Yingchao
Li, Bingsi
Sun, Lei
He, Xin
Wu, Shuang
Shi, Fan
Niu, Li
A prospective randomized comparison of the efficacy of standard antiviral therapy versus ultrasound-guided thoracic paravertebral block for acute herpes zoster
title A prospective randomized comparison of the efficacy of standard antiviral therapy versus ultrasound-guided thoracic paravertebral block for acute herpes zoster
title_full A prospective randomized comparison of the efficacy of standard antiviral therapy versus ultrasound-guided thoracic paravertebral block for acute herpes zoster
title_fullStr A prospective randomized comparison of the efficacy of standard antiviral therapy versus ultrasound-guided thoracic paravertebral block for acute herpes zoster
title_full_unstemmed A prospective randomized comparison of the efficacy of standard antiviral therapy versus ultrasound-guided thoracic paravertebral block for acute herpes zoster
title_short A prospective randomized comparison of the efficacy of standard antiviral therapy versus ultrasound-guided thoracic paravertebral block for acute herpes zoster
title_sort prospective randomized comparison of the efficacy of standard antiviral therapy versus ultrasound-guided thoracic paravertebral block for acute herpes zoster
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815626/
https://www.ncbi.nlm.nih.gov/pubmed/35107389
http://dx.doi.org/10.1080/07853890.2022.2031267
work_keys_str_mv AT mayingchao aprospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT libingsi aprospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT sunlei aprospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT hexin aprospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT wushuang aprospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT shifan aprospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT niuli aprospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT mayingchao prospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT libingsi prospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT sunlei prospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT hexin prospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT wushuang prospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT shifan prospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster
AT niuli prospectiverandomizedcomparisonoftheefficacyofstandardantiviraltherapyversusultrasoundguidedthoracicparavertebralblockforacuteherpeszoster